A study at The University of Queensland and Japan’s Shiga University of Medical Science has revealed blood lactate is a key biomarker that can predict physical outcomes and prognosis in patients with ALS.
ALS – or Amyotrophic Lateral Sclerosis – is the most common form of motor neurone disease (MND) and gradually and inevitably erodes a person’s ability to control voluntary muscle and movement, and to breathe on their own.
Shiga University neurologist Dr Ryutaro Nakamura said the findings could inform treatment and care to help ALS patients retain weight and survive for longer.
“Lactate is an essential metabolic fuel and has long been known to influence motor neuron survival,” Dr Nakamura said.
“This includes supporting the metabolic demands associated with ALS.
“Simply put, the more…